BRISTOL-MYERS' CEFADROXIL IMPORT EXCLUSION REQUEST DENIED -- for a second time -- in a Dec. 18 advisory opinion from International Trade Commission Administrative Law Judge Janet Saxon. The opinion contradicts a Dec. 8 Washington, D.C. federal appeals court ruling that Bristol-Myers Squibb's cefadroxil monohydrate patent "is likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). Saxon's ruling, however, supports her earlier decision, on June 13, that Bristol's request for a ban on the import of generic cefadroxil should not be granted on the grounds that the patent is likely to be held invalid. * Saxon found that Bristol's Bouzard crystalline cefadroxil monohydrate patent would have been "obvious" to a bench chemist of "ordinary skill." The '657 patent was filed March 16, 1982. The ITC judge wrote that a skilled chemist, motivated to create commercially viable, pure and high-yielding product, could have through experimentation arrived at the Bouzard product. She stated that a chemist could have produced the Bouzard monohydrate by modifying two different Bristol patents: the Garbrecht patent ('282) which discloses a process for making purified cephalosporins and the expired Crast patent ('741), which covered cefadroxil in any form. Saxon also concluded that "indirect evidence" supporting the validity of the narrower Bouzard patent, i.e. commercial success of Bristol's Duracef antibiotic and the failure of others to make the product, is "inadequate to overcome the substantial direct evidence that the product claimed would have been obvious." Biocraft and Purepac were co-respondents in the ITC investigation; Zenith also has an approved ANDA for the product but has delayed marketing until disposition of the case. The administrative law judge's opinion will be forwarded to the full ITC commission, which must decide by March 15 whether cefadroxil importation should be banned. Because Purepac and Biocraft are currently marketing the product, an adverse decision will expose them to a claim for damages by Bristol-Myers Squibb. Any decision made by the full commission is subject to appeal in the federal circuit court. In a Dec. 18 press release, Biocraft commented that it is "gratified with the result" and "will continue to market" generic cefadroxil. Court documents show that Biocraft had accrued gross sales of $6.7 mil. for generic cefadroxil from the beginning of March through mid-April. A Bristol-Myers Squibb spokesperson said Dec. 18 that the company was "surprised" that Saxon ignored the appellate ruling that the patent is valid.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.
Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.